Physician profile
Roxy Gazaway
NPI 1487279139
$3,270.55
in general payments reported to CMS, 2019-2025
33 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $417 · 2023: $1,137 · 2024: $455 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,259 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,258.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
| Education | $177.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323.77 | 2021-2024 | |
| Amgen INC. | $300.00 | 2025 | Blincyto |
| Astellas Pharma US INC | $273.36 | 2023-2025 | Vyloy, Padcev, Xospata |
| Daiichi Sankyo INC. | $242.31 | 2022-2024 | Enhertu |
| Lilly USA, LLC | $207.63 | 2022 | |
| Janssen Biotech, INC. | $173.41 | 2023-2025 | Rybrevant, Erleada, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $160.56 | 2023 | Reblozyl, Opdualag |
| Seagen INC. | $146.53 | 2023 | Padcev, Adcetris, Tukysa |
| Jazz Pharmaceuticals INC. | $133.20 | 2025 | |
| Novartis Pharmaceuticals Corporation | $125.98 | 2024-2025 | |
| Mylan Specialty L.P. | $123.51 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $109.99 | 2023-2025 | Tagrisso, Calquence, Imfinzi |
| Kite Pharma, INC. | $107.15 | 2023 | |
| Sanofi-Aventis U.S. LLC | $92.99 | 2025 | |
| Adc Therapeutics America, INC. | $75.24 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $73.03 | 2023-2024 | |
| Stemline Therapeutics INC. | $67.13 | 2023 | Orserdu |
| Gilead Sciences, INC. | $58.28 | 2023-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $54.32 | 2024 | Tavalisse, Rezlidhia |
| Celgene Corporation | $51.21 | 2025 | Reblozyl |
| Incyte Corporation | $50.75 | 2025 | Jakafi, Pemazyre, Monjuvi |
| Emd Serono, INC. | $38.64 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $37.10 | 2024 | Libtayo |
| Tactile Systems Technology INC | $31.40 | 2023 | Entre Plus, Flexitouch Plus |
| Bayer Healthcare Pharmaceuticals INC. | $30.29 | 2023-2024 | |
| Aveo Pharmaceuticals, INC. | $28.52 | 2024 | |
| Merck Sharp & Dohme LLC | $24.83 | 2024 | Keytruda |
| Glaxosmithkline, LLC. | $24.42 | 2025 | Ojjaara |
| G1 Therapeutics, INC. | $23.57 | 2023 | Cosela |
| Exelixis INC. | $22.22 | 2023 | Cabometyx |
| Taiho Oncology, INC. | $21.32 | 2025 | |
| Genmab U.S., INC. | $20.17 | 2025 | Epkinly |
| Puma Biotechnology, INC. | $17.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxy Gazaway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.